Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2024
Details : Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 23, 2021
Lead Product(s) : EI-001
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 06, 2021
Lead Product(s) : EI-001
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 26, 2020
Lead Product(s) : EI-1071
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2020
Lead Product(s) : EI-1071
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable